Reminder of Lufax Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy LU?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, resulting in investor losses when the truth emerged, which negatively impacted the company's reputation and investor confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record, thereby enhancing investor trust.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to effectively protect their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LU
About LU
LUFAX HOLDING LTD is a holding company mainly engaged in providing financial services for small and micro enterprises. The Company's core retail credit enablement business includes bank-funded loans, trust-funded loans and consumer finance loans. The Company is also engaged in wealth management and providing access to financial products and services. The Company conducts the business through its subsidiaries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Lufax class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Lufax made false and misleading statements during the class period, resulting in investor losses when the true details emerged, highlighting inadequate internal controls and materially misstated financial results.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success in the field, prompting investors to carefully select experienced legal counsel.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Lufax Securities Class Action Notice Issued
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiffs by May 20, 2026, or risk losing their chance for compensation.
- Fee Structure: Investors joining the Lufax class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Lufax made false and misleading statements during the class period, failing to disclose inadequate internal controls and materially misstated financial results, which could adversely affect the company's reputation and stock price once the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company, highlighting its expertise and resource advantages, thus investors are advised to select experienced legal counsel to safeguard their interests.
See More
Lufax Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lufax for investors who purchased securities between April 7, 2023, and January 26, 2025, seeking damages for losses incurred due to false statements.
- Allegation Details: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, misleading investors regarding the company's business and prospects, thereby harming their legal rights.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiff in the lawsuit to protect their rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive litigation experience dedicated to providing legal support for investors.
See More
Lufax Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Pomerantz LLP has filed a class action lawsuit against Lufax, alleging securities fraud and other unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiffs by May 20, 2026, highlighting serious concerns over corporate governance and transparency.
- Auditor Change Controversy: On January 27, 2025, Lufax announced plans to replace its auditor, PricewaterhouseCoopers, due to significant concerns regarding the company's financial disclosures for 2022 and 2023, leading to a loss of reliance on the audit opinions, which has raised red flags in the market.
- Stock Price Volatility: Following the auditor change announcement, Lufax's American Depositary Shares plummeted nearly 22% over three trading sessions, reflecting deep investor concerns about the company's financial health and potentially impacting its future fundraising capabilities.
- Law Firm Background: Pomerantz LLP is a prominent firm in securities class litigation, established over 85 years ago, focusing on advocating for victims of securities fraud, with a track record of multimillion-dollar recoveries for class members, indicating strong legal support for the plaintiffs in this case.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax (NYSE:LU) is facing a class action lawsuit for securities transactions between April 7, 2023, and January 26, 2025, as investors suffered significant losses due to potential undisclosed related-party transactions, raising serious concerns about the company's financial transparency.
- Auditor Removal: On January 27, 2025, Lufax announced the removal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, leading to a nearly 14% drop in share price that day, indicating a severe loss of market confidence in its financial reporting.
- Internal Control Deficiencies: The class action alleges that Lufax lacked adequate internal controls and materially misstated its financial results, with investors learning the truth on January 27, 2025, prompting a swift market reaction that heightened concerns over corporate governance.
- Investigation and Consequences: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and disclosure requirements, and if confirmed, this could lead to broader legal liabilities and financial losses, significantly impacting the company's future operations and investor confidence.
See More
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Lufax class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Lufax made false and misleading statements during the class period, resulting in investor losses when the true details emerged, highlighting inadequate internal controls and materially misstated financial results.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success in the field, prompting investors to carefully select experienced legal counsel.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Lufax Securities Class Action Notice Issued
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiffs by May 20, 2026, or risk losing their chance for compensation.
- Fee Structure: Investors joining the Lufax class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Lufax made false and misleading statements during the class period, failing to disclose inadequate internal controls and materially misstated financial results, which could adversely affect the company's reputation and stock price once the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company, highlighting its expertise and resource advantages, thus investors are advised to select experienced legal counsel to safeguard their interests.
See More
Lufax Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Lufax for investors who purchased securities between April 7, 2023, and January 26, 2025, seeking damages for losses incurred due to false statements.
- Allegation Details: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, misleading investors regarding the company's business and prospects, thereby harming their legal rights.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiff in the lawsuit to protect their rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive litigation experience dedicated to providing legal support for investors.
See More
Lufax Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Pomerantz LLP has filed a class action lawsuit against Lufax, alleging securities fraud and other unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiffs by May 20, 2026, highlighting serious concerns over corporate governance and transparency.
- Auditor Change Controversy: On January 27, 2025, Lufax announced plans to replace its auditor, PricewaterhouseCoopers, due to significant concerns regarding the company's financial disclosures for 2022 and 2023, leading to a loss of reliance on the audit opinions, which has raised red flags in the market.
- Stock Price Volatility: Following the auditor change announcement, Lufax's American Depositary Shares plummeted nearly 22% over three trading sessions, reflecting deep investor concerns about the company's financial health and potentially impacting its future fundraising capabilities.
- Law Firm Background: Pomerantz LLP is a prominent firm in securities class litigation, established over 85 years ago, focusing on advocating for victims of securities fraud, with a track record of multimillion-dollar recoveries for class members, indicating strong legal support for the plaintiffs in this case.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax (NYSE:LU) is facing a class action lawsuit for securities transactions between April 7, 2023, and January 26, 2025, as investors suffered significant losses due to potential undisclosed related-party transactions, raising serious concerns about the company's financial transparency.
- Auditor Removal: On January 27, 2025, Lufax announced the removal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, leading to a nearly 14% drop in share price that day, indicating a severe loss of market confidence in its financial reporting.
- Internal Control Deficiencies: The class action alleges that Lufax lacked adequate internal controls and materially misstated its financial results, with investors learning the truth on January 27, 2025, prompting a swift market reaction that heightened concerns over corporate governance.
- Investigation and Consequences: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and disclosure requirements, and if confirmed, this could lead to broader legal liabilities and financial losses, significantly impacting the company's future operations and investor confidence.
See More
